Zoetis (ZTS) closed at $123.78, up 1.26% from the previous day, outperforming the S&P 500. The stock has risen 0.15% in the past month, trailing the Medical sector and S&P 500 gains. Analysts predict an EPS of $1.4 in the upcoming earnings report, with a revenue estimate of $2.36 billion, up 1.89%.

Investors should monitor Zoetis for any changes in analyst estimates, as these revisions impact stock performance. The Zacks Rank system, with a #3 ranking for Zoetis, indicates potential. Zoetis trades at a Forward P/E ratio of 19.3, below the industry average. The Medical – Drugs industry holds a Zacks Industry Rank of 70.

Zacks experts identify 5 stocks poised to double in value, including disruptive forces and growth leaders. These picks offer substantial growth potential, with previous recommendations delivering impressive returns. Download the free Atomic Opportunity report for insights into nuclear energy’s resurgence and access the latest stock recommendations from Zacks Investment Research.

Read more at Nasdaq: Zoetis (ZTS) Outperforms Broader Market: What You Need to Know